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Long-term follow-up after 
thoracic radiotherapy:
symptomatic heart disease 
is an ominous sign
Summary
Background: Thoracic radiotherapy (RT), es-
pecially with past technology, may affect the
heart, but rarely leads to symptoms. In pa-
tients with symptomatic heart disease after
RT, outcome seems to be dismal.
Methods: In this observational descriptive
study, clinical characteristics, findings of ECG,
echocardiography, cardiac interventions and
follow-up were analysed in patients with prior
RT and symptomatic heart disease. The pa-
tients were identified in the echocardiography
database during a ten year period. 
Results: There were 25 patients who had tho-
racic RT at a median age of 35 years (range:
9–59) for lymphoma (12 patients), breast can-
cer (9) or other cancer (4). At least likely inclu-
sion of the heart in the target volume of previ-
ous RT was present in of 16 of 20 patients with
detailed information on RT. Last follow-up was
24 years (range: 5–57) after RT at a median age
of 56 years (range: 30–84). Symptoms (≥1 per
patient) included: dyspnea (21 patients),
angina (12) and/or heart failure (10). Three pa-
tients had prior myocardial infarction. The fol-
lowing disease was found: moderate valvular
disease in 19 patients (76%), coronary artery
disease in 12 (48%), abnormal ECG in 18
(72%), relevant conduction system disease in 9
(36%), restriction / constriction in 7 (28%), and
pericardial effusion in 4 (16%). Cardiac sur-
gery was necessary in 12 patients (death in 2
patients), percutaneous coronary interven-
tions in 5 and pacemaker implantation in 3.
Endocarditis occurred in 2 patients. During
follow-up (21 ± 8 months), death occurred in 
6 patients (24%) and was due to heart disease
in 5 of them.
Conclusions:  If symptomatic heart disease de-
velops in the long-term follow-up after RT,
complex disease of valves, coronary arteries,
conduction system, myocardium and peri-
cardium is frequently observed. Cardiac inter-
ventions are often necessary; and heart dis-
ease may be a common cause of death in these
patients. Careful assessment and evaluation
of treatment options are needed in this patient
group.
Key Words: thoracic radiotherapy; coronary ar-
tery disease; conduction system disease; heart
disease
Introduction
Since 1902, radiation therapy is used for treat-
ment of Hodgkin’s disease and lymphomas.
Initially, the heart was considered to be rela-
tively radio-resistant. In long-term follow-up
of cured patients, cardiac damage was found to
be more frequent than expected [1]. Pericar-
dial disease (acute or delayed pericarditis) was
the earliest described cardiac side-effect of tho-
racic radiotherapy (RT) with an incidence of
2.5–20% depending on the use of subcarinal
blocks shielding the heart [2, 3]. Before effec-
tive chemotherapy regimens became avail-
able, patients with a relapse often underwent
re-RT for breast cancer and lymphomas. Clin-
ically silent cardiac disease after RT has been
found in up to 96% of the patients consisting
of symptomatic or occult constrictive peri-
carditis (50–96%), coronary artery disease
(13%), myocardial fibrosis (up to 50%) and left
ventricular dysfunction (5%) [3–5]. Valvular
abnormalities occur with a high prevalence
(especially aortic valvular disease) even in
asymptomatic patients [6]. Coronary artery
disease is frequent and may typically manifest
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with ostial stenosis of the left main and right
coronary arteries occurring at a mean time of
16 years after RT [2, 7]. Conduction system
disease may consist of bundle branch block,
and first or higher degree atrioventricular
block [6]. A history of prior RT increases the
rate of cardiac mortality two- to threefold ver-
sus controls which were not radiated [8, 9]. In
one study, this was only seen after a follow-up
of at least 15 years [10].
There is no doubt that improvement of
knowledge and RT technique have diminished
the risk of cardiac damage in cancer patients
[11]. However, we still have to care for patients
with symptomatic heart disease occurring
many years after RT to the chest. In previous
reports [12, 13], cardiac disease in patients in
long-term follow-up after RT for lymphoma
was described, and the need for life-long car-
diac follow-up and correction of cardiac risk
factors other than RT was demonstrated [13].
Symptomatic cardiac disease in patients irra-
diated to the chest often seemed associated
with a poor outcome. 
We retrospectively analysed patients with
symptomatic cardiac disease after thoracic RT
focussing on symptoms, type of heart disease,
frequency of combined disease of valves, peri-
cardium, coronary arteries and conduction
system, outcome of cardiac interventions and
long-term follow-up. 
Methods
Study group
Among all 41864 patients in the database referred for an echocardiographic exam to our echocardiography
laboratory within 10 years, there were 25 patients (0.06%) who had both: a history of prior RT to the chest
as well as cardiac symptoms. We reviewed the medical records of these patients focussing on symptoms, coro-
nary risk factors, treatment, interventions and outcome. The median interval between RT and the echocar-
diographic exam in the 25 patients was 24 ± 13 years (range: 5–57). Age at RT was defined as the age of the
patient when RT was started.
Echocardiography
Transthoracic echocardiograms were performed using fully equipped commercially available ultrasound 
instruments (HP 5500 [Hewlett Packard Co., Andover, MA, USA] and Siemens Acuson Sequoia 250 [Moun-
tain View, CA, USA]).
Comprehensive standard 2D and Doppler echocardiography was performed according to the guidelines
of the American Society of Echocardiography [14]. Ejection fraction was calculated by biplane area length
method in all patients.
Diastolic function was assessed as previously described [15]. Criteria for constrictive and restrictive peri-
carditis were used as published [16].
Valvular regurgitation was classified as trivial, mild, moderate or severe according to usual criteria [17].
Aortic stenosis was defined as mild with a mean gradient of 10–29 mm Hg and/or valve area of 1.5–1.9 cm2,
moderate with a mean gradient of 30–49 mm Hg and/or valve are of 1.0–1.5 cm2, and as severe with a mean
gradient of >50 mm Hg and/or valve area of less than 1.0 cm2. Echocardiographic signs for significant heart
disease were defined as described previously for other conditions [18]: at least moderate mitral regurgitation,
at least mild mitral stenosis, at least mild aortic regurgitation or stenosis, at least moderate tricuspid regur-
gitation or at least mild tricuspid stenosis, at least mild pulmonary stenosis, definite signs for constrictive
pericarditis, restrictive filling pattern, a left ventricular ejection fraction of <50% and/or the presence of peri-
cardial effusion.
Systolic pulmonary artery hypertension was defined as systolic pulmonary artery pressure of greater
than 35 mm Hg
ECG analysis
ECG tracings were all retrospectively reviewed. Conduction system disease was defined as complete right or
left bundle branch block, and/or first, second or third degree atrioventricular block (AV block). Incomplete left
anterior hemiblock was not included. Incidence of pacemaker implantations was noted.
Coronary angiography
Routine coronary angiography and heart catheterisation according to standard criteria were performed where
clinically indicated. Coronary artery disease was called significant in the presence of 50% stenosis of a ma-
jor epicardial coronary artery by coronary angiography (or autopsy). If necessary, percutaneous translumi-
nal coronary angioplasty with ballooning with or without stenting was performed as described before [19].
Definition of combined heart disease
Combined heart disease was defined as the presence of significant valvular abnormalities and/or conduction
system pathology (complete right or left bundle branch block, 1st, 2nd or 3rd degree atrioventricular block)
and/or pericardial disease (constrictive/restrictive signs and/or pericardial effusion).
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Data on radiation therapy
The patients received their radiation treatment at different centres in Switzerland and most commonly in
the 1970s and early 1980s. Data were collected as available and a radiation oncologist (P.H.) reviewed all
available data and scored the inclusion of relevant parts of the heart in the target volume as unknown, un-
likely, likely or certain.
Heart surgery
The surgery and hospital records of the 12 patients who underwent cardiac surgery were carefully analysed
focussing on intraoperative findings, type of surgery, complications and length of hospitalisation.
Statistical analysis
Results are presented as mean values ± standard deviation or frequency expressed as a percentage for di-
chotomous or qualitative variables. 
Results
Clinical characteristics
The clinical characteristics of the 25 patients
are summarised in table 1. RT was performed
at a rather young age of 35 ± 14 years. The year
of RT is shown in figure 1. The distribution was
as follows: 7 patients had RT between 1960
and 1970; 7 between 1971 and 1975, 2 between
1976 and 1980, 5 between 1981 and 1985, and
only 4 patients 1986 or later. The two most
common diseases treated with RT were lym-
phoma and breast cancer. At least one cardio-
vascular risk factor was present prior to RT in
18 patients (72%); the average number of coro-
nary risk factors was 1.3. The distribution of
coronary risk factors is shown further down in
table 1. Prior chemotherapy was administered
in 12 patients (48%). Hypothyroidism requir-
ing thyroid hormone replacement was noted in
7 patients (28%). A heart murmur was present
in all patients with significant valvular heart
disease. Dyspnea on exertion and angina were
frequent. A history of heart failure was pres-
ent in 7 of 12 patients with prior chemother-
apy, compared to 8 of 13 patients following RT
alone. A history of myocardial infarction was
present in 3 patients (12%): it was clinically
manifest in only one patient; in two patients a
scar consistent with myocardial infarction was
only discovered at coronary angiography or at
autopsy, respectively.
Patient characteristics including the type
of tumor, treatment and types of heart disease
are summarized in table 2. In 16 of 20 patients
with some or all available details on RT, target
volume including the heart was likely or cer-
tain.
Associated heart disease (as shown in
table 2) included coronary artery disease in 12
patients (48%), valvular heart disease in 19
(76%), pericardial effusion in 4 (16%), diastolic
dysfunction in 8 patients (32%), diminished
left ventricular ejection fraction in 7 patients
(28%), and signs of conduction system disease
with complete right or left bundle branch block
or atrioventricular block in 10 patients (40%).
Echocardiographic findings
The detailed echocardiographic findings are
shown in table 3. The ejection fraction of the
left ventricle ranged from 20 to 78% and was
diminished (<50%) in 8 patients (32%).
Significant aortic valve disease with aortic
regurgitation and/or stenosis was found in 17
patients (68%). The tricuspid valve was rarely
affected. Pulmonary hypertension was quite
frequent and was noted in 7 of 17 patients
(41%) in whom it could be measured. One pa-
tient had stenosis of the right ventricular out-
flow tract at right heart catheterisation; find-
ings of further evaluation with computed
Table 1
Summary of clinical characteristics of the 25 patients at the time of echocardiography. 
Characteristic all patients
Female gender 14 (56%)
Mean age radiation, years (range) 35 ± 14 (9–59)
Mean age last follow-up, years (range) 56 ± 14 (30–84)
Aetiology for radiation
– Lymphoma 12 (48%)
– Breast cancer 9 (36%)
– Other (thymoma, liposarcoma, lung cancer) 4 (16%)
Chemotherapy ever 12 (48%)
Coronary risk factors
– Smoking 12 (48%)
– Arterial hypertension 8 (32%)
– Hyperlipidaemia 6 (24%)
– Positive family history 4 (16%)
– Diabetes mellitus 2 (8%)
Hypothyroidism 7 (28%)
Cardiac murmur 21 (84%)
Dyspnea on exertion 21 (84%)
Angina 12 (48%)
Congestive heart failure ever 10 (40%)
Myocardial infarction 3 (12%)
The number of patients is shown, percentage is indicated in parenthesis.
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tomography were compatible as a calcific rem-
nant of irradiated Hodgkin’s tissue.
Combined heart disease was found in 
18 patients (72%). A typical example is patient
#10 in whom Hodgkin’s disease was treated
with a relatively high dose of radiotherapy 
(48 Gy) and chemotherapy at age 22 years. At
age 37, she developed recurrent pulmonary
oedema due to combined heart disease. She
had severe mitral regurgitation, moderate aor-
tic regurgitation and pericardial effusion as
well as a significant calcific stenosis of her
right coronary ostium. There was also com-
plete left bundle branch block. At heart sur-
gery, it was noted that her atria and the coro-
nary sinus were scarred and small, the aortic
valve was fibrotic; also, the pericardium was
severely fibrotic with changes typical of con-
striction. Aortic and mitral valve replacement
as well as coronary artery bypass grafting with
one bypass to the right coronary artery were
performed. She died postoperatively due to di-
astolic heart failure. At autopsy, severe fibrotic
changes of pericardium and pleura and scar-
ring of the posterior wall of the left ventricle
and septum were found.
Another impressive example is a 43 year
old woman (#22) who developed severe heart
disease with constrictive pericarditis, severe
tricuspid regurgitation and complete atrioven-
tricular block 12 years after RT and
chemotherapy for Hodgkin’s lymphoma. One
year after RT, she had transient pneumonia.
At cardiac surgery 12 years later (tricuspid
valve repair, pericardectomy), severe adhe-
sions over the big, partially calcified vessels,
involving the superior vena cava and anony-
mous vein, were noted, which made surgery
very difficult. The patient barely survived the
operation and postoperative recovery was
lengthy.
A typical echocardiographic example of a
young woman with significant heart disease
15 years after RT (patient #10) is shown in fig-
ure 2. The mitral valve and aortic valve are cal-
cified, shrunk, stenotic, typically, left atrial
size was not increased. Intraoperatively, tissue
of both atria and coronary sinus was shrunk.
In figure 3, an example of a 35 year old woman
with moderate tricuspid regurgitation and se-
vere pericardial constriction is shown; the tri-
cuspid valve was thickened, shrunk, and
showed diminished mobility. 
Figure 1
Distribution of year 
when radiotherapy 
was performed.
Patient, treated radiotherapy heart chemotherapy heart disease
gender cancer (year, age and dose) in field
#1, male Hodgkin´s lymphoma 1979, age 35, 40 Gy certain never CAD, diastolic DF
#2, female cancer bilateral breast 1984, age 52, no data unknown never MR, AR, diastolic DF
#3, female cancer right breast 1984, age 38, no data unlikely never CAD
#4, female cancer right breast 19973, age 59, 50 Gy unlikely never AS
#5, female cancer left breast 1984, age 55, no data unknown never MR
#6, female non-Hodgkin lymphoma 1981, age 56, 24 Gy. certain VACOP CAD, PE, EF dim, 
1991, age 66, re-RT 30 Gy diastolic DF
#7, female sarcoma 1972,age 9, 54 Gy likely endoxan TR, diastolic DF, block
#8, male seminoma 1973, age 35, 60 Gy. certain yes, unknown AS, AR, CAD, block, PE
1980, age 42, re-RT 46 Gy
#9, male Hodgkin´s lymphoma 1967, age 25, 40 Gy likely endoxan block, CAD
#10, female Hodgkin´s lymphoma 1982, age 22, 48 Gy certain CHOP,CLOPP CHF, AR, MR, diastolic DF, 
block, PE, EF dim, CAD
#11, male Hodgkin’s lymphoma 1963, age21, 40 Gy  likely endoxan,MOPP AR, AS, block
#12, female cancer left breast 1968, age 48, no data unknown never AS, CAD, diastolic DF, block
Age is indicated in years; CAD = coronary artery disease; Gy = Gray; CHF = congestive heart failure; PE = pericardial effusion; 
dim EF = diminished left ventricular ejection fraction; diastolic DF = diastolic dysfunction; VACOP, CHOP, CLOPP, MOPP, velbe, 
CCVPP, LMF, COPP, ABVD = different chemotherapy regimens; AS = aortic stenosis; AR = aortic regurgitation; MS = mitral 
stenosis; MR = mitral regurgitation; TR = tricuspid regurgitation.
Table 2
Summary of the 25 patients including data on radiotherapy, chemotherapy and heart disease (part I).
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Figure 4 is the example of a 41 year old pa-
tient with extensive aortic and mitral valve
calcifications including mitral and aortic an-
nulus. He also had impressive calcifications in-
volving the aortic arch.
ECG findings can be summarised as fol-
lows: in 18 patients (72%) the ECG was abnor-
mal with complete right bundle branch block
in 6 patients, complete left bundle branch
block in 3 patients, left anterior hemiblock in
3 patients, and complete AV block necessitat-
ing pacemaker implantation in 3 patients.
First degree AV block was present in 3 pa-
tients. In 6 patients, a history of atrial fibrilla-
tion or flutter was present. 
Cardiac Interventions
Cardiac interventions were performed in 17
patients (63%) and included 13 open heart sur-
geries, percutaneous coronary interventions in
5 patients and 3 pacemaker implantations.
Twelve patients underwent 13 cardiac sur-
geries (12 at our center). Two of 12 patients
(17%) died in the early postoperative period
due to heart failure. Cardiac surgery involved
11 valve replacements or repair in 10 patients,
anterior pericardectomy and right ventricular
epicardiotomy in 1 patient, and coronary ar-
tery bypass grafting due to subtotal left main
stenosis and occlusion of the proximal right
Patient, treated radiotherapy heart chemotherapy heart disease
gender cancer (year, age and dose) in field
#13, female cancer right breast 1967, age 44, no data unlikely never AS, AR
#14, male Hodgkin´s lymphoma 1977, age 35, 44 Gy certain CCVPP + MOPP CAD
#15, female cancer left breast 1964, age 38, no data unknown never AS
#16, female cancer right breast 1988, age 47, 50 Gy unlikely LMF AS, block
#17, female Hodgkin´s lymphoma 1972, age 19, no data likely MOPP-Velbe AR, AS, dim EF
#18, male Hodgkin´s lymphoma 1966, age 21, 30 Gy certain never AR, AS, CAD, dim EF
#19, female bilateral cancer breast 1973, age 43, 40 Gy likely never MR, AS, TR, CAD, block,
including parasternal diastolic DF, dim EF
lymph nodes
#20, male lung cancer 1990, age 47, 50 Gy certain never MR
#21, male Hodgkin´s lymphoma 1975, age 34, 41 Gy certain never AS, AR, block, dim EF
#22, female Hodgkin´s lymphoma 1985. age 31, no data unknown COPP, ABVD MR, MS, CHF, block, 
diastolic DF
#23, male Hodgkin´s lymphoma 1993, age 25, 30 Gy certain MOPP, ABVD CAD, dim EF
#24, male Hodgkin´s lymphoma 1975, age 23, no data likely never AS, CAD
#25, male non-Hodgkin lymphoma 1973, age 13, no data likely never AS, PE
Age is indicated in years; CAD = coronary artery disease; Gy = Gray; CHF = congestive heart failure; PE = pericardial effusion;
dim EF = diminished left ventricular ejection fraction; diastolic DF = diastolic dysfunction; VACOP, CHOP, CLOPP, MOPP, velbe,
CCVPP, LMF, COPP, ABVD = different chemotherapy regimens; AS = aortic stenosis; AR = aortic regurgitation; MS = mitral 
stenosis; MR = mitral regurgitation; TR = tricuspid regurgitation.
Table 2
Summary of the 25 patients including data on radiotherapy, chemotherapy and heart disease (part II).
Table 3
Echocardiographic findings in the 25 patients.
Characteristic all 25 patients
LVEDD, cm (range) 4.6 ± 0.8 (3.2–6.0)
Left atrial size, cm (range) 3.8 ± 1.0 (2.1–6.8)
LV-EF, % (range) 54 ± 15 (20–78)
Aortic regurgitation
– No/trivial regurgitation 11 (44%)
– Mild regurgitation 9 (36%)
– Moderate or severe regurgitation 5 (20%)
Aortic stenosis
– No aortic stenosis 13 (52%)
– Mild aortic stenosis 3 (12%)
– Moderate or severe aortic stenosis 9 (36%)
Mitral valve prolapse 4 (16%)
Mitral regurgitation
– No/trivial or mild regurgitation 19 (76%)
– Moderate or severe regurgitation 6 (24%)
– Mild mitral stenosis 1 (4%)
Tricuspid valve prolapse 1 (4%)
Tricuspid regurgitation
– No/trivial or mild regurgitation 22 (88%)
– Moderate or severe regurgitation 3 (12%)
Pulmonary hypertension* 7 (41%)
Mitral annulus calcification 7 (28%)
Pericardial effusion 4 (16%)
Stenosis right ventricular outflow tract 1 (4%)
* Measured in 17 patients.
LVEDD = left ventricular end-diastolic diameter; LV-EF = left ventricular 
ejection fraction.
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Figure 2
Echocardiographic image in a 37 year old female (patient
#10) 15 years after previous radiotherapy with extensive cal-
cifications of mitral and aortic valve.
There is the parasternal long axis view of the young patient
#10 who died after mitral and aortic valve replacement. 
It shows the calcific mitral and aortic valve. Typically, these
patients may have normally sized (shrunk?) atria despite
atrioventricular regurgitation. 
LV = left ventricle; AO = aorta; LA = left atrium.
Figure 3
This is the image of the 35 year old woman (patient #17)
with postactinic changes on both sides of the heart with
mitral annulus calcification, mitral and aortic valve sclerosis
as well as pronounced tricuspid annulus calcification and
shrunk, thickened tricuspid valve leaflets.
RV = right ventricle; RA = right atrium; LA = left atrium; LV
= left ventricle. Small arrow: tricuspid annulus calcification.
Large arrow: tricuspid valve leaflets.
Figure 4
Aortic and mitral valve disease in a 41 year old man (patient # 9) 18 years after RT for Hodgkin’s disease.
A Extensive calcifications involving the aortic and mitral valve including mitral and aortic annulus. This is the apical long-axis
view showing the severely calcified aortic valve (large arrow). Also the mitral valve is moderately calcified (small arrow).
RV = right ventricle; LV = left ventricle; LA = left atrium; AO = aorta.
B Pronounced calcifiactions of the aortic arch especially at the take-off of the brachiocephalic trunk. This is the aortic arch
where calcific plaques are shown even at the origin of the cerebral arteries (broken arrow). 
BCT = brachiocephalic trunk; IV = innominate vein; AO = aorta.
A
B
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coronary artery in 1 patient. In this last pa-
tient, intraoperatively, the tissue was de-
scribed as friable and not compatible with nor-
mal coronary artery disease. This patient 
developed as a complication aneurysmatic
dilatation of the left main coronary artery due
to the friable tissue of the stenotic coronary
artery after pericardial patch repair. Another
patient had previous mitral valve replacement
and underwent reoperation two years later for
severe constriction and severe tricuspid regur-
gitation with a very prolonged hospital course.
The average stay for heart surgery at our hos-
pital was 9.5 ± 2.8 days; however, some pa-
tients were referred to another hospital for
subsequent postoperative care.
Successful percutaneous transluminal an-
gioplasty was performed in 5 patients. There
were no unusual complications.
One patient had a pacemaker implanta-
tion as the only intervention.
Follow-up and causes of death
Follow-up after the echocardiographic exami-
nation was performed by the end of March
2000 by a clinical visit or notice of death in all
patients; follow-up time was 21 ± 8 months. Six
patients died. In at least five of these patients,
the cause of death was related to heart disease.
The findings, presumed causes of death and
findings at autopsy (if available) in these 6 pa-
tients are summarised in table 4. Endocardi-
tis occurred in 2 patients (14%). In one patient,
staphylococcal endocarditis developed 2 years
after aortic valve replacement and was the
cause of death. This patient had additional se-
vere RT-induced changes including bilateral
carotid artery stenosis, pericarditis and sub-
stituted hypothyroidism 15 years after RT. In
another patient, streptococcal endocarditis de-
veloped in combined aortic valve disease of a
tricuspid aortic valve, she underwent aortic
valve replacement. 
Patient age RT cardiac findings complications and cause of death
age death
#5 55 years severe MR, MVP, mild TR, atrial fibrillation Age 65: mitral valve replacement. Age 69: 
59 years peripheral arterial emboli with rhabdomyo-
lysis and renal failure. Death. Autopsy: 
pericardial adhesions, old posterior 
myocardial infarction, moderate CAD, 
dilated atria.
#9 27 years Stenosis RVOT (gradient 42 mm Hg), total AV block, PTCA LAD, PM, pulmonary oedema, atrial 
41 years CAD (2 vessel) fibrillation. Sudden cardiac death, no autopsy.
Sudden cardiac death 3 days after last 
cardiologic visit.
#10 22 years severe MR, moderate AR, pulmonary hypertension, CHF since age 29. Age 37: mitral/aortic valve
37 years restriction/constriction replacement and CABG. Death 2 days later 
due to diastolic heart failure (restriction/ 
constriction). Autopsy: massive fibrosis of 
pericardium, pleura, old posterior MI.
#12 48 years severe AS, mild MR Age 67: CABG. Age 79: AVR, postoperative 
79 years death (low output), no autopsy
#19 44 years severe AS, mild AR, moderate MR, severe TR, Age 68: dyspnea, CHF, oedema, sudden 
68 years occluded RCA, diminished LV-EF, massive restriction, cardiac death. Autopsy: tricuspid severely 
constriction, LBBB calcific aortic valve, scar posteriorly due to 
occluded RCA, myocardial fibrosis, mitral 
valve sclerosis.
#25 14 years prior pericarditis, moderate AS, mild AR, Age 28: acute pericarditis. Age 33: AVR,
36 years pericardial effusion, stenotic carotid arteries CABG to RCA. Age 39: endocarditis with 
coagulase negative staphylococcus, 
septicaemia with multiorgan failure and 
death. No autopsy.
MR = mitral regurgitation; MVP = mitral valve prolapse; TR = tricuspid regurgitation; CAD = coronary artery disease; 
RVOT = right ventricular outflow tract; AV = atrioventricular; PTCA = percutaneous coronary angioplasty; LAD = left anterior 
descending coronary artery; PM = pacemaker; AR = aortic regurgitation; CHF = congestive heart failure; CABG = coronary artery
bypass grafting; MI = myocardial infarction; AS = aortic stenosis; AVR = aortic valve replacement; MI = myocardial infarction; 
TR = tricuspid regurgitation; RCA = right coronary artery; LV-EF = left ventricular ejection fraction; LBBB = left bundle branch 
block; AR = aortic regurgitation.
Table 4
Patient history, cardiac findings and causes of death in the 6 patients who died.
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Discussion
Our data show what happens if symptomatic
heart disease develops in the long-term follow-
up after RT to the chest – especially with the
old RT technology used up to the early 1980s.
Complex combined disease of valves, coronary
arteries, conduction system, myocardium and
pericardium may be present with many com-
plications and a poor prognosis. Cardiac inter-
ventions in this patient group are frequently
necessary. Careful long-term follow-up is
needed in this patient group.
Significant heart disease following RT to
the chest is rare; in an analysis done at the
University Hospital in Zurich including 352
patients treated for Hodgkin´s lymphoma, a
group of 112 patients underwent cardiac
check-up including echocardiography. Nearly
all these patients had been treated with <2.0
Gy per fraction to the anterior cardiac region.
Sclerosis of mitral and/or aortal valves were
observed in 36 of them (32%), but most were
not clinically significant: only 1 patient had
moderate aortic stenosis and one patient mod-
erate mitral regurgitation [12]. 
Spectrum of radiation induced 
heart disease
Pericardial disease
Acute or delayed pericarditis is the earliest de-
scribed and most widely recognised form of ra-
diation induced cardiac disease [20]. Time to
onset of pericarditis ranges from 4 months to
several years after RT and may present with
pericardial effusion or manifest as constrictive
pericarditis. Most patients with severe peri-
cardial disease have received >40 Gray with
little or no subcarinal shielding. Greenwood
reported a 7% incidence of constrictive peri-
carditis [21]. Hancock described a 4% risk of
constrictive pericarditis requiring pericardec-
tomy [3]. In our patients, the incidence of a re-
strictive and/or constrictive physiology was
28%; however, severe constrictive pericarditis
requiring surgery was rare.
Valvular heart disease
It has been controversial whether valvular ab-
normalities may be considered as a late effect
of RT. In a necropsy report, Brosius described
12 instances of mural endocardial fibrosis and
13 cases of valvular endocardial fibrosis [5].
Hancock found that 12 of 635 patients treated
with RT for Hodgkin’s disease died of cardiac
disease (RR: 29.6; 95% confidence interval
[CI]: 16.0 to 49.3) including seven deaths from
acute myocardial infarction ([AMI] RR: 41.5;
95% CI: 18.1 to 82.1), three from valvular heart
disease, and two from radiation pericarditis /
pancarditis. Three patients underwent valve
replacement, 29 other patients had new mur-
murs [3]. Fifty percent of these patients had
received 44 Gray without subcarinal block-
ing. In our series, valvular abnormalities 
were common (at least moderate valvular
heart disease in 76%), as we collected our pa-
tients from the echocardiography database
which, because of the selection bias, overesti-
mates the prevalence of valvular changes.
However, we believe that valvular abnormali-
ties do have an impact on overall mortality in
this patient group due to endocarditis and
need for valve surgery. In 3 of the 6 patients
who died during short-term follow-up, valvu-
lar heart disease was the likely cause. In a re-
cent paper, Heidenreich et al. reported that in
294 asymptomatic patients with previous me-
diastinal irradiation due to Hodgkin’s disease
with a mean mantle irradiation dose of 43 ± 0.3
Gy, valvular heart disease was common and in-
creased with time following irradiation [6].
The number needed to screen to detect one can-
didate for endocarditis prophylaxis was only
1.6 (95 % CI: 1.3 to 1.9) for those treated at
least 20 years ago. The most common findings
included at least mild aortic regurgitation in
60%, at least moderate tricuspid regurgitation
in 4% and aortic stenosis in 16% in these
asymptomatic patients [6]. This is very simi-
lar to the findings in our paper with 56% of pa-
tients having at least mild aortic regurgita-
tion, 48% at least mild aortic stenosis and 12%
at least moderate tricuspid regurgitation. 
Coronary artery disease after radiation
therapy
Coronary artery disease and acute myocardial
infarction seem to be increased in patients late
after irradiation with a relative risk of 41.5 for
acute myocardial infarction in the Stanford co-
hort [22]. Left main and ostial right coronary
stenosis seem to be typical [7]. In one study,
thallium-201 scintigraphy in patients after
mediastinal RT was abnormal in 85% of these
patients [23]. Mean time at diagnosis of coro-
nary artery disease was 16 years after RT. 
In animal studies, RT alone produced only
rare changes in the media of larger vessels but
animals also given high-cholesterol diet were
noted to have marked atherosclerosis [24].
Other coronary risk factors seem to potentiate
the risk of development of typical epicardial
stenosis in these patients [13]. Coronary ar-
tery disease was present in 48% of our pa-
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tients. Many of our patients have other coro-
nary risk factors. RT is an important risk fac-
tor for coronary artery disease so that patients
with a history of prior thoracic RT should con-
trol other cardiovascular risk factors rigidly.
An additional cardiac risk factor in this patient
group is hypothyroidism which can occur after
mediastinal radiation [25]. This should be ag-
gressively treated. Additionally, if hypothy-
roidism develops after prior mediastinal radi-
ation, concomitant cardiac disease has to be
sought.
Conduction system disease
Conduction abnormalities have been observed
as very late effects especially in patients who
did not receive subcarinal blocking. ECG ab-
normalities have been described in 46–48% of
patients [2, 26, 27]. In 1996, in a letter it was
noted that advanced degrees of heart block are
unusual in heart disease due to RT [28]. In our
patients, conduction abnormalities were fre-
quent, but pacemaker implantation was rarely
required. Still, careful follow-up and evalua-
tion of syncope or dizziness with Holter moni-
toring in this patient group is essential.
Surgery 
The risk of cardiac surgery in patients after
mediastinal RT is increased [29, 30]. Mortal-
ity in our small group was 17%. Surgery is of-
ten more difficult due to the radiation changes
produced on the pericardium and epicardium
of the heart. The thickened valves are more dif-
ficult to repair and frequently lead to valve re-
placement [31]. The risk of valve replacement
with previous mediastinal radiation therapy is
increased in the presence of constrictive peri-
carditis, reduced preoperative ejection fraction,
and larger cardiopulmonary bypass times [29].
In a series of the Mayo Clinic, early mortality
in patients undergoing valve replacement was
40% [29]. 
The plane between pericardium and great
vessels is at times totally blurred with no clear
separation between the pericardium and the
epicardium of the right ventricle or the adven-
titia of the aorta. This fusion of tissue signifi-
cantly increases the risk of iatrogenic injury
while preparing the heart and great vessels.
The coronary lesions are located predomi-
nantly in the ostial or proximal regions of the
epicardial vessels [30]. The mammary arter-
ies, after previous mediastinal radiation, are
frequently unsuitable vessels for bypasses.
The stiffness of the tissues, including the heart
itself, makes the exposure of the valves and
coronary arteries more difficult. 
Finally, the risk of mediastinitis is in-
creased due to the decreased microvasculari-
sation of the sternum and the increased me-
chanical stress applied on the sternum to ob-
tain correct exposure.
Limitations
There is no way to definitely diagnose or ex-
clude radiation-induced heart disease. RT
should be considered as a risk factor in addi-
tion to the common coronary risk factors of
coronary artery disease or degenerative dis-
ease of valves or conduction system. However,
looking at the patient histories of these symp-
tomatic patients, the cardiac changes in clini-
cally symptomatic patients are definitively
more severe than in a comparable population
of the same age.
This is an observational study. Thus out-
come of patients can not be linked with cer-
tainty to the individual exposure.
Radiotherapy to the chest is still com-
monly used in Hodgkin’s disease, breast can-
cer and other malignancies. Nowadays, total
doses are less than in earlier regimens and
fractionated over a 4- to 5-week period which
reduces the incidence of radiation induced
damage. Most of our patients (84%) had their
radiotherapy before 1985. Besides, respiratory
gating and intensity-modulated radiation
therapy are among the techniques being inves-
tigated to reduce cardiac exposure [11]. How-
ever, even modern techniques might not elim-
inate cardiac toxicity completely.
Tissue Doppler imaging or strain rate im-
aging was not performed in any of these pa-
tients, thus systolic and diastolic dysfunction
might have been underestimated.
Conclusions
Patients with a history of RT to the chest have
an increased incidence of cardiac disease. If
symptomatic heart disease develops in the
long-term follow-up after high dose mediasti-
nal irradiation, complex, combined disease of
heart valves, coronary arteries, myocardium,
and conduction system as well as diastolic dys-
function is frequent. Cardiac interventions in
patients after chest irradiation with sympto-
matic heart disease are more complex and dif-
ficult and require prolonged and special care.
We recommend regular cardiac follow-up with
history, physical examination, rigorous control
of cardiovascular risk factors, ECG recordings,
exercise testing, echocardiography, Holter
monitoring and/or computed tomography of
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the chest in the presence of symptoms or a
heart murmur in patients with a previous his-
tory of mediastinal RT.
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